Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Vericel Reports Third Quarter 2024 Financial Results

VCEL : 56.50 (+2.82%)
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

VCEL : 56.50 (+2.82%)
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

/PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments...

SGTX : 22.47 (-2.56%)
ATRS : 5.59 (unch)
VCEL : 56.50 (+2.82%)
Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

Kytopen , an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to...

VCEL : 56.50 (+2.82%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 56.50 (+2.82%)
OCEL : 2.7500 (unch)
BRTX : 1.5500 (+6.90%)
MDXG : 9.10 (+0.22%)
NNVC : 1.4900 (+2.76%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 2.7500 (unch)
BRTX : 1.5500 (+6.90%)
MDXG : 9.10 (+0.22%)
NNVC : 1.4900 (+2.76%)
VCEL : 56.50 (+2.82%)
Vericel (VCEL) Q2 2022 Earnings Call Transcript

VCEL earnings call for the period ending June 30, 2022.

VCEL : 56.50 (+2.82%)
Vericel Reports Second Quarter 2022 Financial Results

Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE,...

VCEL : 56.50 (+2.82%)
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful...

VCEL : 56.50 (+2.82%)
Vericel (VCEL) Q1 2022 Earnings Call Transcript

VCEL earnings call for the period ending March 31, 2022.

VCEL : 56.50 (+2.82%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar